• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

    2/14/22 3:57:49 PM ET
    $SRRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRRA alert in real time by email
    SC 13G/A 1 d9177244_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Sierra Oncology, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

     

    82640U404
    (CUSIP Number)

     

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

    CUSIP No 82640U404    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Caxton Corporation  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,119,322  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,119,322  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,119,322  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     
     
     

    CUSIP No 82640U404    

     

         
    1. NAME OF REPORTING PERSONS  
         
      CDK Associates, L.L.C.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,052,157  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,052,157  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,052,157  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      6.6%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

    CUSIP No 82640U404    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Bruce S. Kovner  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,119,322  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,119,322  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,119,322  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     
     
     


    CUSIP No
    82640U404    

     

    Item 1. (a). Name of Issuer:  
           
        Sierra Oncology, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    1820 Gateway Drive, Suite 110

    San Mateo, CA 94404

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Caxton Corporation

    CDK Associates, L.L.C.

    Bruce S. Kovner

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Caxton Corporation

    731 Alexander Road, Bldg. 2, Suite 500

    Princeton, New Jersey 08540

     

    CDK Associates, L.L.C.

    c/o Caxton Corporation

    731 Alexander Road, Bldg. 2, Suite 500

    Princeton, New Jersey 08540

     

     

    Bruce S. Kovner

    c/o Caxton Corporation

    731 Alexander Road, Bldg. 2, Suite 500

    Princeton, New Jersey 08540

     

     

      (c). Citizenship:  
           
       

    Caxton Corporation – Delaware corporation

    CDK Associates, L.L.C. – Delaware limited liability company

    Bruce S. Kovner – United States citizen

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, $0.001 par value per share  

     

      (e). CUSIP Number:  
           
        82640U404  

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

     

      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     
     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    1,119,322 shares deemed beneficially owned by Caxton Corporation

    1,052,157 shares deemed beneficially owned by CDK Associates, L.L.C.

    1,119,322 shares deemed beneficially owned by Bruce S. Kovner

     

      (b)   Percent of class:
         
       

    7.0% deemed beneficially owned by Caxton Corporation

    6.6% deemed beneficially owned by CDK Associates, L.L.C.

    7.0% deemed beneficially owned by Bruce S. Kovner

     

      (c)   Number of shares as to which Caxton Corporation has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,119,322 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,119,322 .

     

      Number of shares as to which CDK Associates, L.L.C. has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,052,157 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,052,157 .

     

      Number of shares as to which Bruce S. Kovner has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,119,322 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,119,322 .

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

     

         
     

     
     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

     

    The shares of the Issuer reported herein are held in the accounts of CDK Associates, L.L.C., and another entity for which Caxton Corporation is deemed to have beneficial ownership. Bruce S. Kovner is the Chairman and sole shareholder of Caxton Corporation.

     

       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

      

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

      

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

      

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Caxton Corporation*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      CDK ASSOCIATES, l.l.c.*
         
     

    By: Caxton Corporation, its manager

     

      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
       
      BRUCE S. KOVNER*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 14, 2022

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G Amendment No. 1 dated February 14, 2022 relating to the Common Stock, $0.001 par value per share of Sierra Oncology, Inc., shall be filed on behalf of the undersigned.

      Caxton Corporation
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      CDK ASSOCIATES, l.l.c.
         
     

    By: Caxton Corporation, its manager

     

      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
       
      BRUCE S. KOVNER
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 14, 2022

     

     
     

     

    Exhibit B

     

    POWER OF ATTORNEY

     

    Know all by these presents, that the undersigned hereby constitutes and appoints Heath Weisberg, signing singly, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

    (1) execute for and on behalf of the undersigned any applications, reports, or documents required or deemed appropriate by the attorney-in-fact to file pursuant to (i) the United States Securities Exchange Act of 1934, as amended, or any rule, or regulation thereunder, including, without limitation, Schedules 13D, 13G, 13F, and 13H, and Forms 3, 4, and 5, (ii) the Securities Act of 1933, as amended, or any rule or regulation thereunder, including, without limitation, Form 144, (iii) the U.S. Commodity Exchange Act, as amended or any rule or regulation thereunder, or (iv) the statutes, rules or regulations of any other domestic or foreign governmental or self-regulatory authority;

    (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such applications, reports, or documents;

    (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with the applicable statutes, rules and regulations.

    This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or otherwise terminated by my death or other event described in section 5-1511 of the New York General Obligations Law.

    SIGNATURE AND ACKNOWLEDGMENT:

     

    In Witness Whereof I have hereunto signed my name on the 9th day of May, 2013.

    /s/ Bruce Kovner

    Bruce Kovner

     
     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May 2013, before me, the undersigned, personally appeared Bruce Kovner, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

    /s/ Cynthia Rosel Rivera

    Notary Public

     

    AGENT’S SIGNATURE AND ACKNOWLEDGMENT OF APPOINTMENT:

     

    I, Heath N. Weisberg, have read the foregoing Power of Attorney. I am the person identified therein as agent and attorney-in-fact for the principal named therein.

    I acknowledge my legal responsibilities.

    /s/ Heath N. Weisberg

    Heath N. Weisberg

     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May, 2013, before me, the undersigned, personally appeared Heath N. Weisberg, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

    /s/ Cynthia Rosel Rivera

    Notary Public

    Get the next $SRRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRA

    DatePrice TargetRatingAnalyst
    1/31/2022$35.00 → $51.00Buy
    HC Wainwright & Co.
    11/30/2021$33.00 → $39.00Overweight
    Cantor Fitzgerald
    11/5/2021$29.00 → $35.00Buy
    HC Wainwright & Co.
    9/27/2021$33.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

      – Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. "Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team designed a targeted study to address the highest unmet need and delivered incredible results in the midst of a pandemic. We are thrilled to submit this ND

      6/17/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

      – Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also present with thrombocytopenia – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi

      5/12/22 10:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Financials

    Live finance-specific insights

    See more
    • Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

      —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpoints. "These data are extremely exciting and everything we had hoped to see from the trial," said Step

      1/25/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

       —Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings

      8/5/21 4:05:00 PM ET
      $AZN
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $51.00 from $35.00 previously

      1/31/22 9:32:16 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Sierra Oncology with a new price target

      Cantor Fitzgerald reiterated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $39.00 from $33.00 previously

      11/30/21 8:05:31 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $35.00 from $29.00 previously

      11/5/21 12:45:48 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

      RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze

      4/25/22 8:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in

      11/10/21 4:15:00 PM ET
      $ORIC
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/11/22 4:30:36 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

      SC 13G/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/5/22 5:06:15 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      5/6/22 4:33:35 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Sierra Oncology Inc.

      15-12G - Sierra Oncology, Inc. (0001290149) (Filer)

      7/11/22 4:01:52 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:18 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:23 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Vivo Opportunity, Llc returned $183,123,160 worth of shares to the company (3,329,512 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:59:45 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Orbimed Advisors Llc returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:50:05 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ashiya Mona returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:46:16 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care